Edward Medina, M.D.

Dr. Medina received his undergraduate degree in Molecular and Cell Biology from the University of California, Berkeley. He graduated from the Physician-Scientist (M.D./Ph.D.) Training Program at the University of California, Davis, and then completed a residency in Anatomic and Clinical Pathology followed by a fellowship in Hematopathology at UT Health San Antonio. He is board-certified in clinical pathology and hematopathology. He is currently an Assistant Professor of Pathology in the School of Medicine at UT Health San Antonio. He is a clinically active physician with a specialty in hematopathology. He directs a research program that is focused on mechanistically understanding how obesity/insulin resistance/diabetes influences the development/progression of multiple myeloma (MM), as well as their role in chemoresistance, in order to identify novel targets for clinical translation. His laboratory has generated compelling preliminary evidence which suggests that elevated levels of oxidized low-density lipoprotein (OxLDL) contribute to resistance against proteasome inhibitors (PI) in MM patients with hypercholesterolemia/dyslipidemia. They are conducting a series of in vitro and in vivo studies that aim to reveal key pathways involved in mediating the protective effect of OxLDL against PI-induced MM cell killing, and evaluate the potential of suppressing elevated OxLDL levels associated with hypercholesterolemia/dyslipidemia to enhance MM responsiveness to therapeutic PIs.